Adalimumab biosimilar - Prestige BioPharmaAlternative Names: Humira Biosimilar - Prestige Biopharma; PBP 1502
Latest Information Update: 17 Jan 2017
At a glance
- Originator Prestige BioPharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Arthritis
Most Recent Events
- 17 Jan 2017 Preclinical trials in Arthritis in Singapore before January 2017 (Parenteral) (Prestige BioPharma Pipeline, January 2017)